Skip to content
Screener

Citius Oncology, Inc. CTOR Q2 2026 earnings

Reported May 15, 2026 · Before market open

Revenue$1.7MMiss by $5.3M
EPS-$0.27Miss by $0.26
Revenue estimate$7.0M
EPS estimate-$0.01

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$54.72M-17.8%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

FAQ

When did Citius Oncology, Inc. report Q2 2026 earnings?
Citius Oncology, Inc. (CTOR) reported Q2 2026 earnings on May 15, 2026 before market open.
What were Citius Oncology, Inc.'s Q2 2026 revenue and EPS?
Citius Oncology, Inc. reported revenue of $1.7M and eps of $-0.27 for Q2 2026.
Did Citius Oncology, Inc. beat estimates in Q2 2026?
Revenue missed the consensus estimate of $7.0M by $5.3M. EPS missed the consensus estimate of $-0.01 by $0.26.
Where can I find Citius Oncology, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-057883) and the 10-Q periodic report (0001213900-26-057841) directly on SEC EDGAR. The filing index links above go to sec.gov.